The MEDDIC Sales Process, and Why the Letters Are the Easy Part

A good doctor does not diagnose from across the waiting room. She could, often, and be right more than chance would allow, the gray pallor, the careful way a man holds one side as he sits. But she does not stake your life on the look of you. She takes the vitals first: the pressure, the pulse, the blood drawn and sent down the hall. The numbers are not the diagnosis. They are what keeps the diagnosis true, the cold facts that do not care how hopeful anyone felt that morning.

A sales forecast is a diagnosis, and most are made from across the waiting room. A rep looks at a deal, likes the champion, remembers a good call, and writes “commit” next to a number. It feels like judgment. It is mostly the gray pallor and a hopeful morning. MEDDIC is the set of vitals for a deal, the readings you take so the call you make next quarter is grounded in something colder than how the last conversation felt.

What is the MEDDIC sales process?

The MEDDIC sales process is a qualification framework that forces a rep to replace their optimism about a deal with six facts they can prove. It was built at Parametric Technology Corporation in the 1990s, during the years the company grew from around 300 million dollars to more than a billion, and the people who ran that sales floor, Dick Dunkel and Jack Napoli chief among them, left with a discipline that has outlived the company and spread through enterprise software ever since.

Strip away the acronym and MEDDIC is one idea, repeated six times: stop telling yourself a story about the deal, and go find out what is true. A rep who “feels good” about a deal has a story. A rep who can name the number the buyer will move, the person who controls the budget, and the insider who will argue the case when the room is closed, has evidence. The gap between those two reps is the gap between a forecast you can bank and one you cross your fingers over.

What does MEDDIC stand for?

Six letters, each a fact about the buyer, not a thing you did. Take them one at a time, because the difference between knowing the word and knowing the deal lives in the detail.

• Metrics. The economic result the buyer is trying to move, stated as a number they own. Not “improve efficiency,” but “cut ramp time from nine months to five.” If you cannot put a figure on the prize, the buyer has not decided it is worth chasing, and neither have you.
• Economic buyer. The one person who can free the money when the rest of the committee can only ask for it. Champions are common; economic buyers are scarce, and a deal that has never met one is a deal sold to people who can say no but never yes.
• Decision criteria. The standard the buyer will judge you against, technical, commercial, and political. Win the criteria early and you have shaped the race. Learn them at the proposal stage and you are running someone else’s.
• Decision process. The literal sequence of who signs what, in what order, and by when. This is the map of the buyer’s machine, and a deal with no decision process named is a deal whose close date you invented.
• Identify pain. The specific cost the buyer feels now, sharp enough to act on this year. Mild pain produces pleasant conversations and no purchase orders. Qualified pain has a price tag and a deadline the buyer, not you, supplied.
• Champion. The insider with power and a personal stake in your win, who will sell for you when you are not in the room (the role descends directly from the Coach in Miller Heiman’s Strategic Selling). The test is simple and most “champions” fail it: will this person spend their own credibility to push your deal forward, or do they only enjoy the meetings?

That last distinction is the one teams get wrong most, so it earns a picture. A coach likes you. A champion fights for you. A coach takes your calls, shares the gossip, tells you that you are doing great. A champion stands up in the budget meeting you were never invited to and spends real capital arguing that the company should buy. You can have a dozen coaches and zero champions, and the deal will feel warm right up to the day it dies.

Is the MEDDIC sales methodology the same as a sales process?

No. The MEDDIC sales methodology is the six-letter test; the MEDDIC sales process is that test wired into your stages and your weekly rhythm, which is what this page is about. The confusion sounds pedantic and is the reason a large share of rollouts stall. A sales process is where a deal sits on its path, the stages from prospect to close. A methodology is how you work inside those stages. The stages tell you where you are; MEDDIC tells you whether the ground under you is solid. You want both, and they answer different questions, which is the same point we draw out in the seven sales process steps and in what a sales process is.

Here is why the difference bites. A team that treats MEDDIC as a process bolts six new fields onto the CRM, declares the rollout done, and waits for better forecasts that never come. The fields fill up with the same optimism they were meant to replace, because no manager checks whether “Economic buyer: confirmed” means the rep met them or merely hopes they exist. MEDDIC was never a place to store answers. It is a standard for whether the answers are true, and MEDDIC qualification, done properly, is the act of testing each of the six against the buyer rather than against the rep’s memory of the buyer.

Where does each MEDDIC letter belong in your pipeline stages?

A rollout that asks for all six letters on the first day of a deal gets six guesses. No buyer has walked a rep through their decision process on a first call, and a rep forced to fill that field will invent one. MEDDIC starts running as a process when each letter is tied to the stage where a buyer could reasonably have answered it, and the deal cannot leave that stage until the buyer has.

Picture a canal climbing a hill. A boat does not go up in one leap; it rises through a flight of locks, and the gate ahead opens only when the water in the chamber has come level. The crew does not argue with the gate. A pipeline built this way works the same: each stage is a lock, each exit gate names the letters that must be level with evidence, and a deal rises one chamber at a time.

The gates we use, and the reason each letter sits where it does:

• Out of discovery: Identify pain and Metrics. The buyer has named a cost they feel and a number they own. These come first because a buyer who cannot price the problem will not sit through an evaluation.
• Into proposal: Decision criteria, Economic buyer, and Decision process. The buyer has written down, in their words, what they will judge on; a rep has met the person who can free the money; and the steps, names, and dates to a signature are mapped. Criteria come early because a committee argues about what matters before it agrees who signs, and a proposal sent before the economic buyer is met is a price quote to someone who cannot say yes. A champion should be named by this gate, though not yet tested.
• Into commit: a tested Champion and all six at evidence. The champion has done something for you (set the meeting you could not get, forwarded your case to the economic buyer), and every letter has a buyer fact behind it. For deals with a procurement or security review, this is where the Paper process letter from MEDDPICC joins the gate.

Two things make this map more than tidy. It defines a stage by what the buyer has done, so the pipeline reports where the buyer stands, alongside the activity your reps logged to get there. And it shrinks the ask: a rep in discovery owes the process two letters, a load a busy person can carry, where six empty fields invite six guesses. In HubSpot you can enforce the gates with conditional stage properties, which make chosen fields required before a deal moves into a stage. A required field checks that a box is filled and cannot check that it is true, which is why the review below exists; the MEDDPICC scorecard template includes a HubSpot tab with these properties and exit rules ready to copy.

What about MEDDICC and MEDDPICC?

Same spine, more vertebrae for deals that need them. MEDDICC adds a second C for Competition, because a deal you are winning on the merits can still be lost to a rival you never asked about. MEDDPICC adds a P for Paper process, the procurement, legal, and security review that ambushes late-stage deals the rep never qualified for. The bigger and more regulated the purchase, the more those two letters earn their place, because the rival and the redline are precisely where a confident pipeline tends to come apart. If your deals routinely stall in legal, you do not have a closing problem. You have a P you never qualified. If you came here for the acronym itself, what MEDDPICC stands for, letter by letter lives in our companion post, with the question to ask for each letter and a free weighted scorecard you can copy into HubSpot.

Why do most MEDDIC rollouts fail?

Because teams install the acronym and skip the behavior, and the acronym was always the easy part. Any rep can recite six letters by Friday. A chatbot can define them in a sentence. What is hard, what was always hard, is getting a busy rep to do the cold, slightly deflating work of MEDDIC on a real deal while the quarter is short and a shortcut is right there: to call the friendly contact and discover they cannot sign, to ask the question whose true answer demotes a “commit” to a “best case.”

That work is unpleasant, which is why it gets skipped, and the cost of skipping it is enormous. In The Jolt Effect, Matt Dixon and Ted McKenna studied more than two and a half million sales conversations and found that between 40 and 60 percent of qualified, interested buyers end in no decision, not lost to a competitor but lost to their own inability to move (Matt Dixon and Ted McKenna, The Jolt Effect, 2022). Read that against MEDDIC and the framework reveals what it is for: most of those dead deals had pain that was real but not sharp, a champion who was only ever a coach, a decision process no rep mapped. MEDDIC is a machine for catching exactly that, but only if a rep runs it, and only if someone can see whether they did.

That visibility is the part no acronym supplies. We asked 198 sales leaders about it, and the answer was stark: 89 percent had a defined sales process and only 36 percent saw their reps follow it (The State of Sales Enablement). A methodology adopted on paper and ignored in the field is not a methodology. It is a poster.

And the modern buyer makes the discipline more valuable, not less. Gartner finds B2B buyers spend only about 17 percent of the buying journey in contact with all the suppliers they are weighing, combined, and that the deciding group now runs from six to ten people who often fall into open disagreement before they choose (Gartner). When you can watch only a sixth of the real decision, you cannot afford to forecast on vibes. The MEDDIC facts, who controls the money, how the choice gets made, who will fight for you, are the few reliable readings you get from a machine running mostly out of view.

What do the people who own MEDDIC say is the hard part?

It is worth pausing here, because we are not the first to notice that the letters are easy and the doing is hard. The two groups who teach MEDDIC to most of the sales world say the same thing, in their own words, and they are worth hearing in full before we add ours.

John Kaplan ran on that PTC sales floor in the 1990s and built Force Management on what he learned there. His picture for MEDDIC is a good one, close to our own. He calls it an X-ray. “You can’t fix your deals or solve your forecasting issues,” Kaplan says, “without having both the x-ray to identify gaps and the treatment so you can fix them.” Force Management is blunt about the failure mode too: “Many sales teams using MEDDIC today treat it as a simple checklist,” they write, and the revenue shows up only when a team runs it as a repeatable process instead. Grant all of it. The x-ray is real, the rigor wins, and a team that qualifies hard beats a team that hopes.

Andy Whyte, whose 2020 book MEDDICC sold past a hundred thousand copies and put the framework in front of a generation of reps, lands on the same nerve from the Champion. He keeps alive the maxim Jack Napoli and Steve Amman coined at the Sales MEDDIC Group: “No Champion, no deal. Big Champion, Big deal!” That line draws the same hard edge: a friendly contact is not a champion. A champion is a person with real power who will spend their own credibility for you, and finding out which one you have is work a rep has to do, on a real deal, this week.

So the field already agrees on the diagnosis. The acronym is the easy part. The rigorous qualifying is the hard part. Here is where we go one step further, and it is a step Kaplan’s own picture invites.

An X-ray finds the fracture. It never sets the bone. The reading is taken in a moment, and the healing happens, or does not, in the days that follow, when someone acts on what the film showed. MEDDIC has the same two halves. The film is the six facts. The treatment is a rep, in the moment the deal is being worked, calling the friendly contact to find out they cannot sign, asking the question whose true answer demotes a “commit” to a “best case.” And the treatment only works if it happens while the deal is still alive, in the moment the rep is working it, not weeks later when the film is read aloud at a pipeline review and the break has already set wrong.

This is where MEDDIC stops being a noun and becomes a verb, and it is the part a CRM field cannot hold. Storing “Economic buyer: confirmed” is the film. It is not the treatment. The treatment is qualification as a behavior: the cold, slightly deflating act performed in the flow of the deal, then inspected so a manager can tell the difference between a rep who met the economic buyer and one who hopes one exists. Storage is the solved problem in 2026. Any tool can hold the answer; any rep or chatbot can recite the six letters. What is unsolved is making the qualifying happen in the moment and seeing whether it did. Tellingly, both camps now agree: Force Management built Xcelerator for AI-guided execution, and MEDDICC built Winni AI and a deal scorer to push the test into the rep’s day. The field is converging on the same conclusion. The film was never enough; the work has to reach the rep while the deal is open.

How do you run a MEDDIC deal review?

The deal review is where the vitals get read, and the common failure looks the same from team to team: the manager asks “is there a champion?”, the rep says yes, and the row turns green. That is a self-report, and a self-report is the rep’s optimism wearing a lab coat. The fix is to change the question. Not “do we have this letter?” but “what did the buyer do or say that proves it?” Run every deal past stage two through that question, one letter at a time, and accept only the evidence a skeptic would accept. The MEDDIC checklist below is the version we use, with what counts and what does not.

• Metrics. Counts: a number the buyer said out loud, in their units (hours a week, days of DSO, dollars of churn). Does not count: the rep’s own ROI estimate, however carefully built.
• Economic buyer. Counts: a meeting held with the person who can free the money, and what they said the deal needs to prove. Does not count: a title found on an org chart.
• Decision criteria. Counts: the buyer’s written list of what they will judge on, in their words. Does not count: what the rep assumes they care about. Gartner puts the typical B2B buying group at six to ten people (Gartner), so a criteria list from one contact is a partial reading at best.
• Decision process. Counts: named steps, named people, dates, including legal and procurement. Does not count: a target close date, which is a hope with a calendar attached.
• Identify pain. Counts: a cost the buyer quantified and owns. Does not count: a feature request, which is a symptom the buyer has already self-diagnosed.
• Champion. Counts: one thing the champion has already done for you (set a meeting you could not get, forwarded your deck to the economic buyer, told you what the competitor said). Does not count: someone who is friendly on calls.

Any letter without accepted evidence is marked unknown, and the deal does not advance on a checkbox. The reason to hold the line is the inspection effect in our own field data: in the State of Sales Enablement 2026, teams that consistently inspect deals against a defined process hit quota at 6.3 times the rate of teams that rarely do. A MEDDIC review that accepts self-reports is not an inspection; it is a meeting.

A 30-minute MEDDIC deal review agenda

To run the review with a whole team rather than one rep at a time, fix the agenda and the clock. Ours covers the deals in commit and best case, weekly, in 30 minutes; earlier deals get the same test in one-on-ones.

• Minutes 0 to 5: what moved. Stage changes since last week, and any letter that went from unknown to evidence. Movement comes first because it is the only good news a forecast can bank.
• Minutes 5 to 20: the letter walk. Each commit and best-case deal, one letter at a time, one question: what did the buyer do or say that proves it? The manager accepts the evidence or marks the letter unknown, and the debate stops there.
• Minutes 20 to 25: one action per unknown. Each unknown letter leaves the room with a next step, an owner, and a date: the call to the economic buyer, the question for the champion, the criteria document to request.
• Minutes 25 to 30: the team pattern. The letter that came back unknown most often across all reps. That letter is next week’s coaching topic, because a letter that fails on the whole team’s deals points at the system around the reps.

The last five minutes are the ones teams cut, and they are the ones that change the system. A single rep with an unknown Champion needs coaching. Eight reps with unknown Champions have a discovery motion that never asks the question, and no amount of one-on-one pressure fixes that.

The trap is the same one every inspection falls into: done by hand, six letters times forty deals eats the manager’s week, so the review shrinks to the top five deals and the self-report creeps back in for the rest. The answer is not fewer reviews. It is lifting the burden of the review off the manager, so the evidence gets checked automatically deal by deal and the manager’s time goes to coaching the letter that came back unknown.

How do you get your sales team to adopt MEDDIC consistently?

Start from where adoption breaks, because it breaks in a predictable spot. A rep does not skip the economic-buyer letter out of laziness. She skips it because the question reached her at the wrong moment (a training session in onboarding, months before the deal where it mattered), in the wrong place (a PDF, far from the screen she works in), with no one checking afterward whether she asked. Those are three facts about the system around the rep, and each has a fix.

• The right moment: the stage change. Psychologist Peter Gollwitzer named plans of the form “when situation X arises, I will do Y” implementation intentions, and a meta-analysis of 94 studies by Gollwitzer and Paschal Sheeran found they had a medium-to-large effect on reaching goals, d = 0.65 (Gollwitzer and Sheeran, 2006). A stage gate is an implementation intention written into the pipeline: when this deal moves to proposal, I confirm I have met the economic buyer. The cue does the remembering so the rep does not have to.
• The right place: inside the CRM workflow. In our State of Sales Enablement research, teams whose process lives in the CRM workflow hit quota at 49 percent, against 15 percent for teams whose process lives in a doc, a wiki, or an LMS. A MEDDIC guide in a shared drive asks the rep to leave the deal to find it.
• Someone checking: a weekly evidence review. The agenda above, run every week, is the 6.3 times lever. Inspection tells the rep the letters matter, and it tells the manager which letter to coach.
• Unknowns treated as useful. A rep who marks a letter unknown has told the manager exactly where to help. Punish unknowns in the review and reps stop writing them down and start writing guesses, which fills the forecast with confident fiction.
• Your best rep’s standard. Before you write the evidence rules, ask your strongest closer how they know they have met the economic buyer and how they tell a champion from a coach. Their answer is the evidence standard, and the team adopts a bar a peer already clears faster than one a consultant invented.

The order matters. Gates without the review become boxes to fill; a review without gates becomes a weekly argument about what “qualified” means. Build both, and adoption stops depending on each rep’s memory and starts depending on the pipeline itself.

How do you make MEDDIC stick?

So here is the way forward, and it is shorter than the problem makes it sound.

• Score the deal, do not store the deal. MEDDIC is a test, not a tab. Each letter gets a real, defensible answer or it gets marked unknown. “Unknown” is the most valuable word in the framework, because it tells the rep exactly where the deal is blind.
• Reach the rep in the moment, not in a quarterly review. The qualification question has to arrive when the rep is working the deal, not weeks later in a pipeline meeting where the true answer is too late to change anything. This is the deeper subject of sales process adoption and of the sales execution gap.
• Measure the answers, not the activity. A logged call records how hard a rep worked. A confirmed economic buyer records that the deal moved. Track both, advance on the second, and your forecast stops flattering you. This is also why thin qualification wrecks the sales forecast long before quarter close.

MEDDIC pairs naturally with the other sales methodologies a rep carries: BANT for fast first-call triage, and consultative selling for the discovery that turns “pain” from a checkbox into a number the buyer owns. All of it ladders up to one playbook, which is what the sales playbook guide is for.

The letters are common property. Any team can learn them over lunch, and most have. Your edge was never the acronym. It is whether your reps run the test on real deals when the number is due and the champion goes dark, and whether you can see that they did. We built Supered as the Business Logic Layer for exactly that: it puts the right qualification question in front of the rep in the moment they are working the deal, and measures whether the answer is evidence or a hopeful morning. The vitals only keep the diagnosis true if someone takes them.